Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Global Healthcare Today.
Press releases published on July 29, 2025
Counterpart Health Appoints Vicky Bruner as Vice President of Operations to Support Expansion and Customer Execution
GlobeNewswire
·
July 29, 2025
WILMINGTON, Del., July 29, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) and a leading AI-powered physician- …
SI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025
GlobeNewswire
·
July 29, 2025
SANTA CLARA, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual …
100th Fisher House Dedicated at Lovell Federal Health Care Center
GlobeNewswire
·
July 29, 2025
North Chicago, IL, July 29, 2025 (GLOBE NEWSWIRE) -- A new Fisher House was dedicated at the Captain James A. Lovell Federal Health Care Center (Lovell FHCC) by Lovell FHCC Director Dr. Robert Buckley, Deputy Director, Commanding Officer NMRTC Great Lakes …
DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report
GlobeNewswire
·
July 29, 2025
Châtillon, France, July 29, 2025 DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage …
DBV Technologies publie son Rapport Financier Semestriel 2025 ― Modalités de mise à disposition ou de consultation
GlobeNewswire
·
July 29, 2025
Châtillon, France, le 29 juillet 2025 DBV Technologies publie son Rapport Financier Semestriel 2025 ― Modalités de mise à disposition ou de consultation DBV Technologies (Euronext : DBV – ISIN : FR0010417345 - Nasdaq : DBVT), une société biopharmaceutique …
Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025
GlobeNewswire
·
July 29, 2025
DURHAM, N.C., July 29, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2025 …
Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire
·
July 29, 2025
ALACHUA, Fla. and TAMPA, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management will …
DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results
GlobeNewswire
·
July 29, 2025
Châtillon, France, July 29, 2025 DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, …
DBV Technologies publie ses résultats financiers du 2ème trimestre et 1er semestre 2025
GlobeNewswire
·
July 29, 2025
Châtillon, France, le 29 juillet 2025 DBV Technologies publie ses résultats financiers du 2ème trimestre et 1er semestre 2025 DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq Stock Market : DBVT-CUSIP : 23306J309), société biopharmaceutique …
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)
GlobeNewswire
·
July 29, 2025
– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) – – Early PFS data show a trend favoring 30mg onvansertib dose arm vs. control arm – – Onvansertib …
Teladoc Health Reports Second Quarter 2025 Results
GlobeNewswire
·
July 29, 2025
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended June 30, 2025 (“Second Quarter 2025”). Unless otherwise noted, percentage and …
NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025
GlobeNewswire
·
July 29, 2025
MOUNTAIN VIEW, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the second quarter of …
Ceribell to Participate in the Canaccord Genuity 45th Annual Growth Conference
GlobeNewswire
·
July 29, 2025
SUNNYVALE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane …
Iridex to Report Second Quarter 2025 Financial Results on August 12, 2025
GlobeNewswire
·
July 29, 2025
MOUNTAIN VIEW, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal …
Myriad Genetics to Release Second Quarter 2025 Financial Results on August 5, 2025
GlobeNewswire
·
July 29, 2025
SALT LAKE CITY, July 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2025 earnings conference call at 4:30pm ET on Tuesday, Aug. 5, 2025. The …
LifeMD to Report Second Quarter 2025 Financial Results on August 5
GlobeNewswire
·
July 29, 2025
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and six months ended June 30, 2025 after the close of the U.S. …
Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals
GlobeNewswire
·
July 29, 2025
IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, …
Cardiff Oncology Reports Second Quarter 2025 Results and Provides Business Update
GlobeNewswire
·
July 29, 2025
- Appointed Dr. Roger Sidhu as Chief Medical Officer - - Completed enrollment in randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) - - Announced …
Beta Bionics Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Guidance
GlobeNewswire
·
July 29, 2025
IRVINE, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter ended June 30, 2025 and raised its …
Larimar Therapeutics Announces Proposed Underwritten Public Offering
GlobeNewswire
·
July 29, 2025
BALA CYNWYD, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an …